Manifold MarketsSem KYCDados de resolução verificadosRazoavelmente calibradoPrevisão da comunidade atual
Não 73.9%
Previsores
39
Tipo de pergunta
binary
Metodologia
Play-money forecasting platform
Tipo de fonte
Previsão
Dados do mercado
Atualizado há 10 horas
Desatualizado8/12/23, 08:59 UTC1/01/30, 23:59 UTC
Tendências
Mercados Relacionados
Perguntas relacionadas para dar contexto, não uma comparação de contratos equivalentes.
Will there be an FDA Approved treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome by 2030.
Manifold MarketsWill the FDA approve Viagra as a treatment for Alzheimer's before 2030?
Manifold MarketsWill Lantern Bioworks Lumina treatment be FDA Approved for preventing tooth decay by the end of 2028?
Manifold MarketsBumetanide considered effective in the treatment of genetic Alzheimer's by the end of 2026?
FutuurAny vaccine against Alzheimer's disease to be safe and effective by the end of 2027?
FutuurRaniPill microneedle pill to replace injections: approved for sale by the end of 2026?
FutuurRegras
Semaglutide (brand names: Ozempic, Rybelsus, and Wegovy) is an antidiabetic and anti-obesity drug.
- Its developer, Novo Nordisk, has three ongoing phase 3 trials run across the world of semaglutide for Alzheimer’s disease:
- NCT04777396: 1,840 participants, started in 2021, results expected in 2026,
- NCT05891496: 24 participants, started in 2023, results expected in 2025,
- NCT04777409: 1,840 participants, started in 2021, results expected in 2026.
- Will semaglutide be approved by the Food and Drug Administration (FDA) for Alzheimer's (or any kind of cognitive impairment) before January 1st, 2030?
